Article
Gastroenterology & Hepatology
Maria Chaparro, Ana Garre, Francisco Mesonero, Cristina Rodriguez, Manuel Barreiro-de Acosta, Jesus Martinez-Cadilla, Maria T. Arroyo, Noemi Mancenido, Monica Sierra-Ausin, Isabel Vera-Mendoza, Maria Jose Casanova, Pilar Nos, Carlos Gonzalez-Munoza, Teresa Martinez, Maia Bosca-Watts, Margalida Calafat, David Busquets, Eva Girona, Jordina Llao, Maria Dolores Martin-Arranz, Marta Piqueras, Laura Ramos, Gerard Suris, Fernando Bermejo, Ana Y. Carbajo, Diego Casas-Deza, Agnes Fernandez-Clotet, Maria J. Garcia, Daniel Ginard, Ana Gutierrez-Casbas, Luis Hernandez, Alfredo J. Lucendo, Lucia Marquez, Olga Merino-Ochoa, Francisco J. Rancel, Carlos Taxonera, Antonio Lopez Sanroman, Saioa Rubio, Eugeni Domenech, Javier P. Gisbert
Summary: The study findings indicate that tofacitinib is effective and safe in treating active ulcerative colitis. However, a significant proportion of patients discontinue the drug over time, mainly due to primary failure.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Pharmacology & Pharmacy
Kaituo Huang, Jing Liu, Wenhao Xia, Chuwen Tian, Lingya Yao, Qian Cao, Haotian Chen
Summary: This study evaluated the long-term effectiveness and safety of vedolizumab (VDZ) in Chinese patients with ulcerative colitis (UC). The results showed favorable outcomes in terms of clinical response, clinical remission, and steroid-free clinical remission at both the 14-week and 52-week time points. The most common adverse event during the follow-up period was skin rash, and no new safety signals were found. Overall, the results of this study were similar to previous studies in other geographical regions and populations.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Gastroenterology & Hepatology
Irit Avni-Biron, Ariella Bar-Gil Shitrit, Benjamin Koslowsky, Asaf Levartovsky, Uri Kopylov, Roni Weisshof, Nathaniel Aviv Cohen, Nitsan Maharshak, David Hovel, Eran Israeli, Timna Naftali, Idan Goren, Yfat Snir, Jacob E. Ollech, Hagar Banai-Eran, Yelena Broitman, Tali Sharar-Fischler, Iris Dotan, Henit Yanai
Summary: Tofacitinib showed effectiveness and safety in treating moderate to severe ulcerative colitis in Israeli patients, achieving corticosteroid-free remission in about 20% of patients with extensive biologics experience. Despite some patients continuing to use tofacitinib at 26 weeks, it was well tolerated and safe. Earlier use of tofacitinib in the treatment algorithm may lead to improved outcomes.
DIGESTIVE AND LIVER DISEASE
(2022)
Review
Gastroenterology & Hepatology
Carlos Taxonera, David Olivares, Cristina Alba
Summary: This study confirms the effectiveness of tofacitinib in promoting clinical remission and corticosteroid-free remission in patients with moderate to severely active UC. It also found that tofacitinib has made progress in mucosal healing in UC treatment. Additionally, the safety profile of tofacitinib in UC treatment was found to be acceptable.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Sruthi Adimadhyam, James D. Lewis, Andrew L. Simon, Audrey E. Wolfe, Samantha Smith, Laura Hou, Erick Moyneur, Juliane S. Reynolds, Sengwee Toh, Angela Dobes, Lauren Parlett, Kevin Haynes, Jessica Burris, Jennifer E. Dorand, Millie D. Long, Michael D. Kappelman
Summary: This real-world study evaluated the effectiveness and safety of newly initiating treatment with tofacitinib vs vedolizumab among TNF-experienced patients with UC in a large, geographically diverse US population. The study found that patients initiating tofacitinib had lower treatment persistence compared to those initiating vedolizumab. Further randomized trials are needed to inform clinical practice. Rating: 7 points
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Millie D. Long, Anita Afzali, Monika Fischer, David Hudesman, Maisa Abdalla, Robert McCabe, Benjamin L. Cohen, Ryan C. Ungaro, Will Harlan, John Hanson, Gauree Konijeti, Steven Polyak, Timothy Ritter, Bruce Salzberg, Jennifer Seminerio, Emily English, Xian Zhang, Puza P. Sharma, Hans H. Herfarth
Summary: This study aimed to prospectively describe the efficacy of tofacitinib during induction therapy for UC using a novel electronic reporting tool. The results showed that tofacitinib led to a significant improvement in UC disease activity within a few days of treatment initiation, resulting in steroid-free remission. The study further confirmed the safety profile of tofacitinib.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Tessa Straatmijer, Fiona D. M. van Schaik, Alexander G. L. Bodelier, Marijn Visschedijk, Annemarie C. de Vries, Cyriel Y. Ponsioen, Marieke Pierik, Ad A. van Bodegraven, Rachel L. West, Nanne K. H. de Boer, Nidhi Srivastava, Tessa E. H. Romkens, Jildou Hoekstra, Bas Oldenburg, Gerard Dijkstra, Janneke C. van der Woude, Mark Lowenberg, Zlatan Mujagic, Vince B. C. Biemans, Andrea E. Van der Meulen-de Jong, Marjolijn Duijvestein
Summary: The aim of this study was to evaluate the effectiveness and safety of 24 months of tofacitinib use in patients with ulcerative colitis in the Netherlands. The results showed that 31.8% of patients achieved corticosteroid-free clinical remission after 24 months of tofacitinib treatment. The main side effects were skin reactions and headaches.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Seung Hwan Shin, Kyunghwan Oh, Sung Noh Hong, Jungbok Lee, Shin Ju Oh, Eun Soo Kim, Soo-Young Na, Sang-Bum Kang, Seong-Joon Koh, Ki Bae Bang, Sung-Ae Jung, Sung Hoon Jung, Kyeong Ok Kim, Sang Hyoung Park, Suk-Kyun Yang, Chang Hwan Choi, Byong Duk Ye
Summary: This study investigated the real-life effectiveness and safety of tofacitinib treatment in Korean patients with ulcerative colitis. The results showed that tofacitinib was effective in inducing and maintaining clinical remission in Korean patients with UC, and it had an acceptable safety profile.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Tessa Straatmijer, Vince B. C. Biemans, Marijn Visschedijk, Frank Hoentjen, Annemarie de Vries, Adriaan A. van Bodegraven, Alexander Bodelier, Nanne K. H. de Boer, Gerard Dijkstra, Noortje Festen, Carmen Horjus, Jeroen M. Jansen, Bindia Jharap, Wout Mares, Fiona D. M. van Schaik, Cyriel Ponsioen, Tessa Romkens, Nidhi Srivastava, Michael M. P. J. A. van der Voorn, Rachel West, Janneke van der Woude, Marije D. J. Wolvers, Marieke Pierik, Andrea E. van der Meulen-de Jong, Marjolijn Duijvestein
Summary: This study compared the effectiveness and safety of vedolizumab and tofacitinib in anti-TNF-exposed patients with UC. The results showed that tofacitinib was associated with superior effectiveness outcomes compared with vedolizumab, along with comparable safety outcomes.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Maria Chaparro, Diana Acosta, Cristina Rodriguez, Francisco Mesonero, Miren Vicuna, Manuel Barreiro-de Acosta, Agnes Fernandez-Clotet, Alvaro Hernandez Martinez, Maite Arroyo, Isabel Vera, Alexandra Ruiz-Cerulla, Beatriz Sicilia, M. Jose Cabello Tapia, Carmen Munoz Villafranca, Jesus Castro-Poceiro, Jesus Martinez Cadilla, Monica Sierra-Ausin, Juan Maria Vazquez Moron, Raquel Vicente Lidon, Fernando Bermejo, Vanesa Royo, Margalida Calafat, Carlos Gonzalez-Munoza, Eduardo Leo Carnerero, Noemi Mancenido Marcos, Leyanira Torrealba, Horacio Alonso-Galan, Jose Manuel Benitez, Yolanda Ber Nieto, M. Teresa Diz-Lois Palomares, Maria Jose Garcia, Jose Fernando Munoz, Edisa Maria Armesto Gonzalez, Xavier Calvet, Alejandro Hernandez-Camba, Rosa Eva Madrigal Dominguez, Luis Menchen, Jose Lazaro Perez Calle, Marta Piqueras, Carmen Duenas Sadornil, Belen Botella, Teresa de Jesus Martinez-Perez, Laura Ramos, Maria Carmen Rodriguez-Grau, Elena San Miguel, Jose Luis Fernandez Forcelledo, Paola Maria Fradejas Salazar, Marife Garcia-Sepulcre, Ana Gutierrez, Jordina Llao, Eva Sese Abizanda, Maia Bosca-Watts, Eduardo Iyo, Alma Keco-Huerga, Carmen Martinez Bonil, Elena Pena Gonzalez, Pablo Perez-Galindo, Pilar P. Varela, Javier Gisbert, To ReWard Study Grp
Summary: This study aims to evaluate the durability, short-term and long-term effectiveness, and safety of tofacitinib in ulcerative colitis (UC) in clinical practice. The study found that tofacitinib is effective in both short-term and long-term treatment of UC patients, and its safety profile is consistent with previous reports.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Carlos Taxonera, David Olivares, Olga N. N. Lopez-Garcia, Cristina Alba
Summary: This study provides evidence on the real-world outcomes of ustekinumab for ulcerative colitis (UC) patients. The meta-analysis confirms the effectiveness of ustekinumab in achieving clinical remission and response in a highly treatment-refractory population of UC patients. The safety profile of ustekinumab is also demonstrated with low rates of adverse events and serious infections.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Wei-Chen Lin, Wei-Chen Tai, Chung-Hsin Chang, Chia-Hung Tu, I-Che Feng, Ming-Jium Shieh, Chen-Shuan Chung, Hsu-Heng Yen, Jen-Wei Chou, Jau-Min Wong, Yu-Hwa Liu, Tien-Yu Huang, Chiao-Hsiung Chuang, Tzung-Jiun Tsai, Feng-Fan Chiang, Chien-Yu Lu, Wen-Hung Hsu, Fang-Jung Yu, Te-Hsin Chao, Deng-Chyang Wu, Ai-Sheng Ho, Hung-Hsin Lin, Chun-Lung Feng, Keng-Liang Wu, Ming-Wun Wong, Chien-Chih Tung, Chun-Chi Lin, Chia-Chang Chen, Huang-Ming Hu, Lung-Sheng Lu, Huann-Sheng Wang, I-Chen Wu, Hsin-Yu Kuo, Jia-Feng Wu, Hsiang Yao Shih, Yen-Hsuan Ni, Shu-Lun Tang, Peng-Hsu Chen, Shu-Chen Wei
Summary: This nationwide prospective registry study investigated the real-world effectiveness, safety, and persistence of vedolizumab (VDZ) in inflammatory bowel disease (IBD) patients in Taiwan. Disease relapse rates after VDZ discontinuation due to reimbursement restriction were assessed.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Tamas Resal, Peter Bacsur, Csilla Keresztes, Anita Balint, Renata Bor, Anna Fabian, Bernadett Farkas, Kostas Katsanos, George Michalopoylos, Davide Giuseppe Ribaldone, Mohamed Attauabi, Mirabella Zhao, Hadar Amir Barak, Henit Yanai, Cristina Bezzio, Antonio Rispo, Fabiana Castiglione, Ariella Bar-Gil Shitrit, Daniela Pugliese, Alessandro Armuzzi, Edoardo Vincenzo Savarino, Martin Kolar, Milan Lukas, Elena Chashkova, Rafal Filip, Aurore Rozieres, Stephane Nancey, Zeljko Krznaric, Eszter Schafer, Patricia Szamosi, Patricia Sarlos, Matej Franko, David Drobne, Oleg Knyazev, Anna Kagramanova, Jimmy Limdi, Panu Wetwittayakhlang, Peter L. Lakatos, Nitsan Maharshak, Lian Bannon, Tibor Nyari, Zoltan Szepes, Klaudia Farkas, TFB Study Grp, Tamas Molnar
Summary: Background and Aims: This retrospective, international cohort study aimed to evaluate the efficacy and safety of tofacitinib (TFB) in the treatment of moderate-to-severe colitis and acute severe ulcerative colitis (ASUC). The study found that TFB was effective in both indications and resulted in high rates of steroid-free remission in the short and long terms.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Maria Chaparro, Ana Garre, Marisa Iborra, Monica Sierra-Ausin, Manuel Barreiro-de Acosta, Agnes Fernandez-Clotet, Luisa de Castro, Maia Bosca-Watts, Maria Jose Casanova, Alicia Lopez-Garcia, Rufo Lorente, Cristina Rodriguez, Ana Y. Carbajo, Maria Teresa Arroyo, Ana Gutierrez, Joaquin Hinojosa, Teresa Martinez-Perez, Albert Villoria, Fernando Bermejo, David Busquets, Blau Camps, Fiorella Canete, Noemi Mancenido, David Monfort, Merce Navarro-Llavat, Jose Lazaro Perez-Calle, Laura Ramos, Montserrat Rivero, Teresa Angueira, Patricia Camo Monterde, Daniel Carpio, Irene Garcia-de-la-Filia, Carlos Gonzalez-Munoza, Luis Hernandez, Jose M. Huguet, Victor J. Morales, Beatriz Sicilia, Pablo Vega, Isabel Vera, Yamile Zabana, Pilar Nos, Patricia Suarez Alvarez, Cristina Calvino-Suarez, Elena Ricart, Vicent Hernandez, Miguel Minguez, Lucia Marquez, Daniel Hervias Cruz, Saioa Rubio Iturria, Jesus Barrio, Carla Gargallo-Puyuelo, Ruben Frances, Esther Hinojosa, Maria del Moral, Xavier Calvet, Alicia Algaba, Xavier Aldeguer, Jordi Guardiola, Miriam Manosa, Ramon Pajares, Marta Piqueras, Orlando Garcia-Bosch, Pilar Lopez Serrano, Beatriz Castro, Alfredo J. Lucendo, Miguel Montoro, Elena Castro Ortiz, Francisco Mesonero, Esther Garcia-Planella, David A. Fuentes, Inmaculada Bort, Pedro Delgado-Guillena, Lara Arias, Agueda Iglesias, Marta Calvo, Maria Esteve, Eugeni Domenech, Javier P. Gisbert
Summary: Ustekinumab has shown durability and effectiveness in the treatment of ulcerative colitis, even in real life situations. Higher levels of serum C-reactive protein were associated with a lower probability of achieving remission. In the short term, 53% of patients showed a positive response to the treatment.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Biochemistry & Molecular Biology
Monica State, Paul Balanescu, Theodor Voiosu, Andreea Bengus, Andrei Voiosu, Andrei Coman, Petronel Mustatea, Lucian Negreanu, Radu Bogdan Mateescu, Cristiana Popp
Summary: This study investigated mucosal and histologic remission rates and potential predictors of these outcomes in UC patients. The results showed that mucosal healing and histologic remission rates are low in real-life settings. It was also found that a good quality of life and normal inflammatory markers are associated with mucosal and histologic healing.
